Galectin Therapeutics Inc. (GALT)

Market Cap	168.52M +76.6%
Revenue (ttm)	n/a
Net Income	-30.97M
EPS	-0.48
Shares Out	65.83M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	309,406
Open	2.490
Previous Close	2.470
Day's Range	2.480 - 2.570
52-Week Range	1.210 - 7.130
Beta	1.04
Analysts	Strong Buy
Price Target	8.50 (+232.03%)
Earnings Date	May 14, 2026

About GALT

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. Galectin Ther...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 9
• Stock Exchange: NASDAQ
• Ticker Symbol: GALT
• Website: https://galectintherapeutics.com

Analyst Summary

According to 2 analysts, the average rating for GALT stock is "Strong Buy." The 12-month stock price target is $8.5, which is an increase of 232.03% from the latest price.

Price Target

$8.5

(232.03% upside)

Analyst Consensus: Strong Buy